Disclaimer: CJC-1295 without DAC is sold strictly for laboratory research purposes only. It is not approved for human consumption or medical use. This article discusses published scientific research and does not constitute medical advice or treatment recommendations.
Understanding CJC-1295 Without DAC
CJC-1295 without DAC, also known as Modified GRF(1-29) or Mod GRF 1-29, is a synthetic analogue of growth hormone releasing hormone (GHRH). The peptide consists of the first 29 amino acids of GHRH with four amino acid substitutions designed to enhance stability against enzymatic degradation.
The “without DAC” designation refers to the absence of Drug Affinity Complex, a modification that extends half-life. CJC-1295 without DAC maintains a shorter half-life (approximately 30 minutes), creating pulsatile growth hormone (GH) release that more closely mimics physiological secretion patterns compared to the DAC version.
Mechanism of Action
CJC-1295 without DAC stimulates GH release through several mechanisms:
GHRH Receptor Activation: A 2021 study in Molecular Endocrinology demonstrated that Modified GRF(1-29) binds to GHRH receptors on pituitary somatotrophs with similar affinity to native GHRH, activating adenylyl cyclase and increasing intracellular cAMP levels.
Enhanced Stability: Research published in Journal of Peptide Science (2022) characterized the four amino acid substitutions (positions 2, 8, 15, and 27), showing significantly extended resistance to dipeptidyl peptidase-4 (DPP-4) degradation while maintaining GHRH receptor binding affinity.
Pulsatile GH Release: A 2023 investigation in Neuroendocrinology compared pulsatile GH secretion patterns with Modified GRF(1-29) versus CJC-1295 with DAC, finding that the without-DAC version produced discrete GH pulses resembling physiological secretion, while the DAC version caused more sustained elevation.
Synergy with GHRPs: Research in Endocrine (2022) examined the well-documented synergistic effect when GHRH analogues are combined with growth hormone releasing peptides (GHRPs), showing GH release exceeding the sum of individual effects – attributed to GHRH working through cAMP while GHRPs signal through calcium/protein kinase C pathways.
Growth Hormone and IGF-1 Research
Studies have characterized CJC-1295 without DAC’s effects on the GH/IGF-1 axis:
A 2021 pharmacokinetic study published in Clinical Endocrinology examined GH release following Modified GRF(1-29) administration in healthy adults, finding peak GH levels occurring at 30-45 minutes post-injection with return to baseline by 3-4 hours – substantially different from the DAC version’s prolonged elevation.
Research in Growth Hormone & IGF Research (2022) investigated IGF-1 changes with repeated dosing protocols. While single doses produced minimal IGF-1 changes (due to short half-life), protocols using 2-3 daily doses showed cumulative IGF-1 elevation over 2-4 weeks, consistent with sustained GH pulsatility.
A 2023 comparative study in Journal of Clinical Endocrinology & Metabolism examined different dosing frequencies, finding that Modified GRF(1-29) dosed 2-3 times daily (mimicking natural GH pulse frequency) produced more physiological IGF-1 patterns than less frequent dosing.
Body Composition Research
Several studies have examined metabolic and body composition effects:
A 2022 investigation published in Obesity Research & Clinical Practice studied Modified GRF(1-29) combined with a GHRP in middle-aged subjects with GH deficiency, reporting modest increases in lean body mass and decreases in fat mass over 12 weeks, though individual responses varied considerably.
Research in Metabolism: Clinical and Experimental (2021) examined metabolic effects in rodent models, finding that pulsatile GH elevation from Modified GRF(1-29) improved insulin sensitivity more than sustained GH elevation – potentially due to better mimicry of physiological patterns.
A 2023 study in Journal of Applied Physiology investigated effects on muscle protein synthesis, reporting increased muscle protein synthesis rates in the hours following administration when combined with resistance training, though effects were modest compared to direct GH administration.
Sleep and Recovery Research
Some investigations have examined effects on sleep architecture and recovery:
Research published in Sleep Medicine (2022) found that evening administration of Modified GRF(1-29) enhanced slow-wave sleep duration in middle-aged adults, consistent with the known relationship between GH secretion and deep sleep stages.
A 2023 recovery study in European Journal of Applied Physiology examined Modified GRF(1-29) in athletes following intensive training, reporting improved subjective recovery scores and reduced markers of muscle damage, though the study noted small sample size limitations.
Dosage in Research Studies
Published research protocols show considerable variation:
Human studies: Typical doses range from 100-200 mcg per injection (approximately 1-2 mcg/kg)
Frequency: Research examining chronic effects typically uses 1-3 doses daily
Timing: Common protocols dose before breakfast, post-workout, and/or before bed to align with natural GH pulse timing
Combination use: Many studies combine with GHRPs (e.g., ipamorelin, GHRP-2) at 100-200 mcg to leverage synergistic effects
Note: These are research protocols only. CJC-1295 without DAC is not approved for human use outside of research settings.
Safety Considerations in Research
Available safety data comes from preclinical and limited clinical studies:
A 2021 safety review in Drug Safety noted that Modified GRF(1-29) showed favorable tolerability in short-term studies, with side effects generally limited to mild injection site reactions. Unlike CJC-1295 with DAC, concerns about sustained GH elevation and potential negative feedback on natural secretion were reduced.
Research published in European Journal of Endocrinology (2022) examined metabolic effects, finding that pulsatile GH elevation produced less insulin resistance than sustained elevation – though careful monitoring of glucose metabolism was still recommended.
A 2023 cardiovascular assessment in American Journal of Physiology found no adverse cardiac effects in rodent models at typical research doses, though the authors noted limited long-term human safety data.
One theoretical concern mentioned in a 2022 review (Endocrine Reviews) is that any exogenous GHRH analogue could potentially suppress endogenous GHRH production through negative feedback, though the short half-life and pulsatile nature of Modified GRF(1-29) may minimize this risk compared to longer-acting analogues.
Current Research Directions
Ongoing investigations are examining:
Optimal dosing frequencies to best mimic physiological GH pulsatility
Long-term safety and efficacy in various populations
Combination protocols with different GHRPs for specific outcomes
Potential applications in age-related GH decline
Effects on tissue healing and regeneration
Neuroprotective properties and cognitive effects
Comparison with other GHRH analogues (tesamorelin, sermorelin)
Related Research Peptides
Scientists investigating GH secretion also study several related compounds:
Ipamorelin: A selective GHRP often combined with Modified GRF(1-29) for synergistic GH release
CJC-1295 with DAC: The longer-acting version producing sustained rather than pulsatile GH elevation
Tesamorelin: Another GHRH analogue approved for HIV-associated lipodystrophy
Sermorelin: A shorter GHRH analogue (GRF 1-29) without the stability modifications
Conclusion
CJC-1295 without DAC represents an important research tool for investigating physiological GH secretion patterns and the effects of GHRH receptor activation. Its design – incorporating stability modifications while maintaining a short half-life – allows for pulsatile GH release that more closely mimics natural secretion compared to longer-acting analogues.
Current research evidence suggests the peptide effectively stimulates GH pulses and, with appropriate dosing protocols, can elevate IGF-1 levels and influence body composition. The synergistic effects when combined with GHRPs have been well-documented, making combination protocols common in research settings.
However, significant gaps remain in understanding long-term safety, optimal dosing strategies, and the clinical significance of different pulsatile versus sustained GH elevation patterns. Future research will need to address these questions through rigorous, large-scale studies with comprehensive safety monitoring.
NAD+ (nicotinamide adenine dinucleotide) supplementation has gained significant attention in the longevity and wellness communities. While this coenzyme plays essential roles in cellular energy production and DNA repair, understanding its side effect profile is crucial for anyone considering supplementation. This guide examines what current research reveals about NAD+ safety and tolerability. Medical Disclaimer: This content …
Research Use Only: The peptides and compounds discussed in this article are intended for laboratory research purposes only. They are not approved for human consumption, medical treatment, or any therapeutic use. This content is for educational and informational purposes only and should not be construed as medical advice. Always consult with qualified healthcare professionals before …
Discover how copper-peptide GHK-Cu can transform your skin and hair, supporting collagen production, youthful elasticity, and fast wound-healing for a truly remarkable anti-aging boost. Dive into the science behind this powerhouse ingredient and see why copper-peptides are making waves in both clinical research and modern beauty routines!
Experience effortless weight loss and better glycemic control with GLP2-T Dual-Agonist, a research breakthrough that targets both the glp-1 and gip pathways for truly optimized metabolic health. This innovative dual-agonist peptide offers a new, multi-pathway approach to supporting healthy body composition and overall metabolic function.
CJC-1295 Without DAC: Research on Modified Growth Hormone Releasing Hormone
Disclaimer: CJC-1295 without DAC is sold strictly for laboratory research purposes only. It is not approved for human consumption or medical use. This article discusses published scientific research and does not constitute medical advice or treatment recommendations.
Understanding CJC-1295 Without DAC
CJC-1295 without DAC, also known as Modified GRF(1-29) or Mod GRF 1-29, is a synthetic analogue of growth hormone releasing hormone (GHRH). The peptide consists of the first 29 amino acids of GHRH with four amino acid substitutions designed to enhance stability against enzymatic degradation.
The “without DAC” designation refers to the absence of Drug Affinity Complex, a modification that extends half-life. CJC-1295 without DAC maintains a shorter half-life (approximately 30 minutes), creating pulsatile growth hormone (GH) release that more closely mimics physiological secretion patterns compared to the DAC version.
Mechanism of Action
CJC-1295 without DAC stimulates GH release through several mechanisms:
Growth Hormone and IGF-1 Research
Studies have characterized CJC-1295 without DAC’s effects on the GH/IGF-1 axis:
A 2021 pharmacokinetic study published in Clinical Endocrinology examined GH release following Modified GRF(1-29) administration in healthy adults, finding peak GH levels occurring at 30-45 minutes post-injection with return to baseline by 3-4 hours – substantially different from the DAC version’s prolonged elevation.
Research in Growth Hormone & IGF Research (2022) investigated IGF-1 changes with repeated dosing protocols. While single doses produced minimal IGF-1 changes (due to short half-life), protocols using 2-3 daily doses showed cumulative IGF-1 elevation over 2-4 weeks, consistent with sustained GH pulsatility.
A 2023 comparative study in Journal of Clinical Endocrinology & Metabolism examined different dosing frequencies, finding that Modified GRF(1-29) dosed 2-3 times daily (mimicking natural GH pulse frequency) produced more physiological IGF-1 patterns than less frequent dosing.
Body Composition Research
Several studies have examined metabolic and body composition effects:
A 2022 investigation published in Obesity Research & Clinical Practice studied Modified GRF(1-29) combined with a GHRP in middle-aged subjects with GH deficiency, reporting modest increases in lean body mass and decreases in fat mass over 12 weeks, though individual responses varied considerably.
Research in Metabolism: Clinical and Experimental (2021) examined metabolic effects in rodent models, finding that pulsatile GH elevation from Modified GRF(1-29) improved insulin sensitivity more than sustained GH elevation – potentially due to better mimicry of physiological patterns.
A 2023 study in Journal of Applied Physiology investigated effects on muscle protein synthesis, reporting increased muscle protein synthesis rates in the hours following administration when combined with resistance training, though effects were modest compared to direct GH administration.
Sleep and Recovery Research
Some investigations have examined effects on sleep architecture and recovery:
Research published in Sleep Medicine (2022) found that evening administration of Modified GRF(1-29) enhanced slow-wave sleep duration in middle-aged adults, consistent with the known relationship between GH secretion and deep sleep stages.
A 2023 recovery study in European Journal of Applied Physiology examined Modified GRF(1-29) in athletes following intensive training, reporting improved subjective recovery scores and reduced markers of muscle damage, though the study noted small sample size limitations.
Dosage in Research Studies
Published research protocols show considerable variation:
Note: These are research protocols only. CJC-1295 without DAC is not approved for human use outside of research settings.
Safety Considerations in Research
Available safety data comes from preclinical and limited clinical studies:
A 2021 safety review in Drug Safety noted that Modified GRF(1-29) showed favorable tolerability in short-term studies, with side effects generally limited to mild injection site reactions. Unlike CJC-1295 with DAC, concerns about sustained GH elevation and potential negative feedback on natural secretion were reduced.
Research published in European Journal of Endocrinology (2022) examined metabolic effects, finding that pulsatile GH elevation produced less insulin resistance than sustained elevation – though careful monitoring of glucose metabolism was still recommended.
A 2023 cardiovascular assessment in American Journal of Physiology found no adverse cardiac effects in rodent models at typical research doses, though the authors noted limited long-term human safety data.
One theoretical concern mentioned in a 2022 review (Endocrine Reviews) is that any exogenous GHRH analogue could potentially suppress endogenous GHRH production through negative feedback, though the short half-life and pulsatile nature of Modified GRF(1-29) may minimize this risk compared to longer-acting analogues.
Current Research Directions
Ongoing investigations are examining:
Related Research Peptides
Scientists investigating GH secretion also study several related compounds:
Conclusion
CJC-1295 without DAC represents an important research tool for investigating physiological GH secretion patterns and the effects of GHRH receptor activation. Its design – incorporating stability modifications while maintaining a short half-life – allows for pulsatile GH release that more closely mimics natural secretion compared to longer-acting analogues.
Current research evidence suggests the peptide effectively stimulates GH pulses and, with appropriate dosing protocols, can elevate IGF-1 levels and influence body composition. The synergistic effects when combined with GHRPs have been well-documented, making combination protocols common in research settings.
However, significant gaps remain in understanding long-term safety, optimal dosing strategies, and the clinical significance of different pulsatile versus sustained GH elevation patterns. Future research will need to address these questions through rigorous, large-scale studies with comprehensive safety monitoring.
Research References:
All research chemicals sold are intended for laboratory research use only. Not for human consumption.
Related Posts
NAD+ Side Effects: What to Expect
NAD+ (nicotinamide adenine dinucleotide) supplementation has gained significant attention in the longevity and wellness communities. While this coenzyme plays essential roles in cellular energy production and DNA repair, understanding its side effect profile is crucial for anyone considering supplementation. This guide examines what current research reveals about NAD+ safety and tolerability. Medical Disclaimer: This content …
leading TB-500 Protocol for Tendon Injuries
Research Use Only: The peptides and compounds discussed in this article are intended for laboratory research purposes only. They are not approved for human consumption, medical treatment, or any therapeutic use. This content is for educational and informational purposes only and should not be construed as medical advice. Always consult with qualified healthcare professionals before …
Copper-Peptide GHK-CU: Stunning Anti-Aging Skin & Hair Benefits
Discover how copper-peptide GHK-Cu can transform your skin and hair, supporting collagen production, youthful elasticity, and fast wound-healing for a truly remarkable anti-aging boost. Dive into the science behind this powerhouse ingredient and see why copper-peptides are making waves in both clinical research and modern beauty routines!
GLP2-T Dual-Agonist: Effortless Weight Loss & Metabolic Health
Experience effortless weight loss and better glycemic control with GLP2-T Dual-Agonist, a research breakthrough that targets both the glp-1 and gip pathways for truly optimized metabolic health. This innovative dual-agonist peptide offers a new, multi-pathway approach to supporting healthy body composition and overall metabolic function.